secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2022-02-14T23:59:59+00:00
Accession:  0000950170-22-001168
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix reports record full-year 2021 revenue of $54.5M; core lung diagnostic testing up 49%
--------------------------------------------------------------------------------

- Full-year 2021 total revenue $54.5M vs $45.6M in 2020; Q4 revenue $7.2M.
- Core lung diagnostic testing revenue grew 49% YoY; excluding COVID-19, annual core revenue $24.3M (+41%).
- Q4 core revenue (ex-COVID) $6.8M, up 22% YoY and 13% sequentially.
- Cash and cash equivalents $32.7M as of Dec 31, 2021.
- CEO highlights new IQLung and GeneStrat NGS tests; company may seek additional capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022001168/0000950170-22-001168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022001168/bdsx-20220214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-001168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer